{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for flortaucipir in Display Name (approximate match)
Showing 1 - 2 of 2 results
Status:
US Approved Rx
(2020)
Source:
NDA212123
(2020)
Source URL:
First approved in 2020
Source:
NDA212123
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Flortaucipir (18F-AV-1451, also known as 18F-T807) is a highly selective positron emission tomography (PET) imaging agent targeting paired helical filament (PHF)-tau in the brain. This tracer is studying for clinical assessment in patients with various tauopathies, including Alzheimer's disease, as well as in healthy subjects.
Status:
Investigational
Source:
NCT02103894: Phase 1 Interventional Completed Alzheimer's Disease (AD)
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
FLORTAUCIPIR is a gamma-carboline derivative. Its 18F radiolabelled form is a highly selective positron emission tomography (PET) tracer targeting paired helical filament (PHF)-tau in the brain. This tracer is studying for clinical assessment in patients with various tauopathies, including Alzheimer's disease.
